Click the button below to download Prescribing Information (PI) and Adverse Event reporting. A complete overview of EURneffy® can be found in the Summary of Product Characteristics (SmPC) which can be viewed in the links below.
*this is not the actual size of the product
Don’t delay, spray.
* This medicinal product does not require any special storage conditions.1
About EURneffy®
EURneffy® is a nasal adrenaline spray for adults and children, for the emergency treatment of severe allergic reactions (anaphylaxis) due to1:
- Insect bites or stings
- Food, medicines and other allergens
- Idiopathic or exercise-induced anaphylaxis
*this is not the actual size of the product
Dosage
The recommended initial dose is a single nasal administration of 1 mg adrenaline for children aged 4 years and over weighing 15 kg to less than 30 kg, or 2 mg adrenaline for adults and children with a body weight ≥30 kg. Children and adults weighing 30 kg or more should be prescribed EURneffy® 2 mg.1
The patient should be advised to use EURneffy® without delay if anaphylaxis is suspected. In the absence of clinical improvement after 5 minutes, a second dose should be administered in the same nostril. It is recommended that patients should always carry two nasal sprays to treat an allergy emergency.1
Discover key features of EURneffy®
How to use EURneffy®
This short video explains how to use EURneffy® and covers essential topics, including device preparation, administration technique and post-administration guidance.
EURneffy® Training Materials
The EURneffy® trainer device helps patients, caregivers, school nurses and pharmacists become familiar with how it works so they can use it confidently in an emergency.
Prepare your patients to Reach for EURneffy®
Safety Information and special warnings
There are no contraindications for using EURneffy® in an emergency.1
Healthcare Professionals should ensure that patients, and if needed their caregivers, are thoroughly educated on the indications, recognition of anaphylaxis symptoms, and correct use of EURneffy®. Caregivers should administer for children under 12 unless selfadministration is appropriate. EURneffy® may be used with a congested nose, though absorption could be altered. Asthma increases risk, anaphylaxis can recur after initial relief, and adrenaline should be administered promptly at the earliest signs of a severe allergic reaction. Special caution is required in those with cardiovascular, metabolic, or other specific conditions. HCPs should review medication interactions and risks associated with ingredients such as benzalkonium chloride and sodium metabisulphite. Patients must always seek immediate medical assistance after use.1
For full details consult the EURneffy® SmPC
- EURneffy® Summary of Product Characteristics June 2026
October 2026
GB-EURn-2500121